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ABSTRACT
The ‘‘allogeneic effect’’ refers to the induction of host B cell antibody synthesis or host T cell cytotoxicity,
including tumoricidal activity, by an infusion of allogeneic lymphocytes. We show that treatment of mice with
cyclophosphamide (Cy) followed by CD81 T cell-depleted allogeneic donor lymphocyte infusion (Cy 1
CD82 DLI) induces regression of established tumors with minimal toxicity in models of both hematologic
and solid cancers, even though the donor cells are eventually rejected by the host immune system. The optimal
antitumor effect of Cy1CD82DLI required the presence of donor CD41T cells, host CD81T cells, and allo-
antigen expression by normal host but not tumor tissue. The results support a model in which a donor CD41
T cell-mediated graft-versus-host (GVH) reaction effectively awakens antitumor immunity among Cy-resistant
host CD81 T cells. These events provide the cellular mechanism of the ‘‘allogeneic effect’’ in antitumor immu-
nity. Cy1CD82DLImay be an effective and minimally toxic strategy for awakening the host immune response
to advanced cancers.
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Allogeneic blood or marrow transplantation (allo-
BMT) is a well-established therapy for hematologic
malignancies. The graft-versus-leukemia (GVL) effect
of alloBMT is perhaps the best evidence that T cells
can mediate the destruction of advanced, metastatic hu-
manmalignancies via direct killing of tumor cells by do-
nor T cells reactive to host histocompatibility antigens
[1-8].Despite the curativepotentialof allogeneicTcells,
alloBMT as a procedure is severely hampered by 3 fac-
tors: (1) toxicity; (2) lack of efficacy, especially in solid
tumors; and (3) limited availability of human leukocyte
antigen (HLA)-identical donors. The conditioning reg-
imen, infection, and GVHD all contribute to toxicity,
and lack of efficacy manifests itself as progression of
the underlying malignancy after transplantation [9,10].
Recently, there have been reports of disease re-
sponses in patients with hematologic [11-13] or solid[14] malignancies despite rejection of the donor leuko-
cytes. Earlier studies had shown that antitumor effects
can be mediated by donor lymphocyte infusions (DLI)
in patients receiving no or minimal conditioning. In-
terestingly, although alloBMT has not been conclu-
sively shown to be effective in the treatment of solid
tumors, allogeneic or even xenogeneic lymphocyte in-
fusions have induced objective responses in as many as
20%-30% of patients with advanced solid malignan-
cies [15]. These observations raise the question of
whether transiently engrafting lymphocytes mediate
clinical responses via direct killing of tumor cells. Alex-
ander and colleagues [16] were the first to speculate
that cells of the host mediate the antitumor effect of al-
logeneic lymphocytes. Katz et al. [17,18] subsequently
found that allogeneic DLI prolonged the survival of
guinea pigs subsequently challenged with a host strain
leukemia, even when the challenge occurred after the499
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immune system. This was dubbed the ‘‘allogeneic ef-
fect’’ of antitumor immunity, yet the underlying cellu-
lar mechanisms of this effect have been poorly defined.
Here, we have developed a mouse model to investi-
gate the cellular interactions involved in the antitumor
effect of transiently engrafting lymphocytes.These stud-
ies reveal a potential collaboration in which donor
CD41 T cells cooperate with, and effectively awaken,
host CD81 T cells to induce tumor regression in both
hematologic and solidmalignancies.Therefore, infusion
of allogeneic lymphocytes after minimal conditioning
canmediate an antitumor effect against a wide spectrum
of malignancies with reduced toxicity compared with
standard allogeneic bone marrow transplantation.
MATERIALS AND METHODS
Animals
C57BL/6 (B6; H-2b), BALB/c (H-2d, Thy1.21/1),
BALB/c  B6 (CB6) F1 (H-2d/b), and B6  C3H
(B6C3) F1 (H-2
b/k) mice were all obtained from the
National Cancer Institute (Frederick, MD). Mice
were maintained in microisolator cages and were fed
ad libitum with autoclaved laboratory chow and acidi-
fied water. All mice were approximately 6 to 12 weeks
of age at the time of treatment. All manipulations were
performed in a laminar flow hood. The Animal Care
and Use Committee of the Johns Hopkins University
approved all procedures on animals in accordance
with guidelines established by the Association for As-
sessment and Accreditation of Laboratory Animal
Care (AAALAC). In specified GVHD experiments,
mice were weighed semiweekly beginning at the time
of adoptive transfer of lymphocytes.
Tumor Cell Lines
A20 is a spontaneous B cell leukemia/lymphoma of
BALB/c origin [19]. Cells were obtained originally
from American Type Culture Collection (ATCC;
Manassas, VA), and were maintained in culture and
administered intravenously (i.v.) at the lethal dose of
1  106 as previously described [20]. Cells were cul-
tured in vitro in Eagle Hanks Amino Acid (EHAA)
medium (Biofluids, Rockville, MD), 10% fetal calf se-
rum (FCS; GIBCO BRL, Gaithersburg, MD), 5 
1025 M 2-mercaptoethanol (2-ME), glutamine, and
antibiotics (complete medium; CM). RENCA, a mu-
rine carcinogen-induced renal cell carcinoma of
BALB/c origin and B16, a murine melanoma cell line
of C57Bl/6 origin, were used in specified experiments
and maintained in vitro in RPMI 1640 (Life Technol-
ogies, Grand Island, NY), supplemented with 10%
heat-inactivated FCS (HyClone, Logan, UT), 5 
1025 M 2-ME, 20 mmol/L HEPES, 30 Ag/mL genta-
micin (Schering Corporation, Kenilworth, NJ), and
0.2% sodium bicarbonate.Cell Preparations
Donor spleens were removed aseptically and
pressed through a nylon mesh to obtain single cell sus-
pensions. In some experiments, T cells were depleted
from donor splenocytes by incubation with antibodies
to CD4 (RL172.4; gift of Dr Albert Bendelac, U. Chi-
cago, Chicago, IL) and/or CD8 (3.155; ATCC), and
guinea pig complement (GIBCO BRL), as previously
described [21]. Cell suspensions were vigorously pipet-
ted, counted, and washed in sterile phosphate-buffered
saline (PBS) prior to injection. The purity of depleted
cells was greater than 99.4% in all experiments.
Adoptive Transfer of T Cells
Cyclophosphamide (Cy; Bristol-Myers, Evans-
ville, IN) was dissolved in PBS to a concentration of
20mg/mL and administered at a dose of 200mg/kg in-
traperitoneally (i.p.) before or after tumor inoculation
as specified in each experiment. Twenty-five million
splenocytes, prepared as above, were injected i.v. into
the lateral tail vein unless otherwise specified.
In Vivo Depletion of T Cells
Mice were depleted of CD81 T cells in vivo by
giving 1.4 mg 2.43 (rat antimouse CD8 monoclonal
antibody) [22,23] i.p. on days 9 and 30 after tumor in-
oculation. The 2.43 antibody was produced and puri-
fied from the supernatant of a bioreactor cell culture
at the National Cell Culture Center (Division of Biov-
est International, Worcester, MA) and was diluted
in sterile PBS prior to injection. Control mice were
injected with sterile PBS only.
Antibodies and Flow Cytometry
Antibodies for flow cytometry were anti-CD4 (al-
lophycocyanin, peridinin chlorophyll protein [PerCP],
and phycoerythrin-Cy5 [Cyc]), Thy1.1 (FITC, PerCP
and phycoerythrin [PE]), Thy1.2-allophycocyanin and
-fluorescein isothiocyanate (FITC), H-2Kb FITC,
CD-45 PerCP, CD8-PE, and -FITC, and B220-
FITC (eBioscience, San Diego, CA). All antibodies
were purchased from BD Biosciences (Mountain
View, CA) unless otherwise specified. Gated events
were collected on a FACSCalibur (Becton Dickinson,
San Jose, CA) and analyzed using CellQuest software
(Becton Dickinson).
Analysis of Leukocyte Chimerism
At designated times after DLI, blood was obtained
from the lateral tail vein, or animals were killed and
suspensions of spleen and/or bone marrow were pre-
pared. Erythrocytes from the peripheral blood were
lysed by using ammonium chloride buffer before initi-
ation of staining. For determination of lineage-specific
chimerism in BALB/c chimeras, 1 million cells were
stained with fluorescein (FITC)-conjugated antibody
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thrin (PE)-conjugated antibodies to CD4 or CD8 (all
from Becton Dickinson). In each experiment, samples
of peripheral blood from at least 3 host strain mice not
receiving transplants were stained for donor H-2 or
Thy antigens. The mean1 (3  SEM) of the percent-
age of FITC cells in hosts not receiving transplants was
calculated (and was\0.5% for every experiment), and
any transplant recipient containing a greater percent-
age of FITC cells than this value was considered to
have donor cell engraftment.
Lymphocyte Quantification
TruCOUNTTubes (BDBiosciences) were used
for determining absolute counts of leukocytes in blood.
The tubes contain a known number of lyophilized
4.2-mm fluorescent beads. In specified experiments,
peripheral blood was obtained from the lateral tail
vein at specified times after adoptive lymphocyte trans-
fer. Trucountwas performed according to themanu-
facturer’s recommendations. Briefly, 20 mL containing
CD45-PerCP antibody was distributed to each Tru-
count tube. Then 50 mL of peripheral blood from
each mouse was added, gently mixed, and incubated
for 15 minutes at room temperature in the dark. The
lysis and fixation were obtained by adding 450 mL of
FACS Lysing solution (BD Biosciences). Samples
were analyzedwithin 1 hour on a FACSCalibur (Becton
Dickinson). Samples were mixed gently immediately
prior to analysis. Absolute cell count was calculated
using the following formula:
# of events in region containing cell
# of events in absolute count bead region
# of beads per test
test volume
5absolute count of cell
Figure 1. Cy 1Non-engrafting CD8-depleted DLI abrogates risk of GVHD, induces anti-tumor immunity, and prolongs survival of animals
with established, metastatic hematologic and solid tumor malignancies. (A, B) CD8 depletion of DLI abrogates risk of GVHDwithout compro-
mising anti-tumor immunity. BALB/c mice (H-2d; n510/group) either received 106 A20 lymphoma cells IV on Day 0 alone (6) or were con-
ditioned with Cy 200mg/kg IP on day –1 and received 106 A20 lymphoma cells IV onDay 0 (B). Additional mice were then treated with 5 107
whole spleen cells from fullyMHC-mismatchedC57BL/6 (H-2b) donors, either undepleted (-) or depleted of CD41T cells (C), CD81T cells
(:), or both (,). Results for 1A: (:) versus (,) P5.04, (C) versus (,) P5 .3. Results for 1B: (:) versus (B) versus (B) P\ .0001, (:) versus
(,) versus P5 .0002, (B) versus (,) P5 .17. (C) Cy1CD8-depleted allogeneic DLI prolongs survival of animals with established, metastatic
lymphoma. BALB/c mice (H-2d; n510/group) received 106 A20 cells IV onDay 0 either alone (-), or followed by treatment with Cy 200 mg/kg
IP on day 14 (C), or Cy 200 mg/kg IP on day 14 and 5  107 spleen cells from fully MHC-mismatched C57BL/6 (H-2b) donors, depleted of
CD81 T cells on Day 15 (:). Results show: (C) versus (-) P\ .0001, (:) versus (C) P5 .02. (D) Cy1 CD8-depleted allogeneic DLI pro-
longs survival of animals with established, metastatic renal cell carcinoma. BALB/cmice (H-2d; n510/group) received 106 RENCAcells IV alone
onDay 0 either alone (-), or followed by treatment with Cy 200mg/kg IP on day 14 (C), or Cy 200mg/kg IP on day 14 and 5 107 spleen cells
from fully MHC-mismatched C57BL/6 (H-2b) donors, depleted of CD81 T cells on Day 15 (:). Results show: (C) versus (-) P 5 .01,
(:) versus (C) P 5 .001. All experiments were repeated at least once.
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Count Tube foil pouch label.
Statistical Analysis
All survival data were analyzed by the nonparamet-
ric rank sum test of Wilcoxon. P\ .05 was considered
statistically significant. In mice receiving both tumor
and donor lymphocytes, the mechanism of death (tu-
mor versus GVHD) was verified by necropsy of repre-
sentative animals (data not shown).
Medians and SEMs were calculated for lympho-
cyte and chimerism data and analyzed using Sigma
Plot, v9.0 (Systat Software, San Jose, CA). All experi-
ments were repeated at least once.
RESULTS
Cyclophosphamide plusCD81TCell-DepletedDLI
Is Effective against Early and Established,
Metastatic Hematologic, or Solid Cancers
To model the antitumor effects of transiently
engrafting allogeneic lymphocytes, mice were condi-
tioned with cyclophosphamide (Cy) only, a drug that
is minimally toxic to host hematopoietic stem cells.
In the first set of experiments, Cy was administered
the day before tumor challenge, with or without con-
comitant lymphocyte transfusion, so that any antitu-
mor effects observed could be unequivocally
attributed to the lymphocytes and not the drug. In a tu-
mor survival experiment employing BALB/c recipients
and fully MHC-incompatible B6 donors, administra-
tion of Cy followed by 50 million whole splenocytes
led to severe acute GVHD (aGVHD), marked by
hunched posture, ruffled fur, weight loss, diarrhea,
and ultimately death (Figure 1A). In contrast, animals
receiving the same number of splenocytes depleted of
CD81 cells (CD82 DLI) had no clinical evidence of
GVHD and survived longer than animals receiving
Cy plus splenocytes depleted of both CD41 and
CD81 cells (median survival, 60 versus 30 days; P 5
.04). Recipients of CD41 cell-depleted splenocytes
did not survive significantly longer than recipients of
T cell-depleted splenocytes (median survival, 56 versus
30 days; P 5 .30). Therefore, donor CD41 T cells are
required for the optimal antitumor effect of Cy 1
CD8-depleted DLI.
In a second tumor survival experiment employing
BALB/c recipients and fully MHC-incompatible B6
donors (Figure 1B), animals that received CD82
DLI survived significantly longer than mice receiving
Cy alone (median survival, 73 versus 19.5 days; P\
.0001). Additionally, recipients of CD82DLI survived
significantly longer than mice receiving CD42CD82
DLI (median survival, 73 versus 22 days; P 5 .0002).
Furthermore, there was no difference between mice
receiving no DLI (Cy only) and CD42CD82 DLI
(median survival, 19.5 versus 22 days; P 5 .17). Thisexperiment demonstrates that CD42CD82 DLI does
not provide any antitumor benefit over no DLI.
Deaths in mice in Figures 1A and 1B that received
A20 alone, or A20 with Cy conditioning 1/2CD82
DLI or CD42CD82 DLI were secondary to tumor,
as confirmed by necropsy or visualization of protuber-
ant abdomens and/or hindleg paralysis, whereas deaths
in mice receiving whole spleen DLI were solely from
GVHD. Recipients of CD42 DLI died either early
from GVHD or later from tumor.
To investigate the therapeutic potential of Cy 1
CD82 DLI, disseminated tumor was established by
intravenous (i.v.) injection 14 days prior to any treat-
ment. Compared to animals receiving no treatment,
A20- or RENCA (renal cell carcinoma)-bearing
BALB/c mice treated with Cy alone survived a median
of 34 (Figure 1C) or 6 days (Figure 1D) longer (P\
.0001 and P 5 .01) respectively. Addition of CD82
DLI from B6 donors further prolonged survival by
a median of 10 (Figure 1C; P5 .02) and 7 (Figure 1D;
P 5 .001) days, respectively. These data demonstrate
that transiently engrafting allogeneic lymphocytes
achieve modest but significant prolongations of sur-
vival in mice with disseminated hematologic or solid
malignancies.
CD82 DLI Engrafts Transiently and Does Not
Cause GVHD or Leukopenia
The 2 most common complications of transfusing
viable allogeneic lymphocytes into unconditioned
human recipients are severe aGVHD and bonemarrow
aplasia, bothofwhich require the sustainedengraftment
of the donor cells [6,24]. To characterize the toxicities
of Cy 1 DLI, tumor-free BALB/c mice were condi-
tioned with Cy, transfused with 50 million B6 spleno-
cytes, and were monitored serially for survival, and
leukocyte count in the peripheral blood. Additionally,
A20-bearing BALB/c mice were conditioned with Cy,
transfused with 50 million B6 splenocytes, and were
monitored for donor CD41, CD81, and B cell chime-
rism. Recipients of either whole or CD41 T cell-
depleted splenocytes in nontumor bearing mice had
GVHD-associatedmortality (Figure 2C), and leukope-
nia prior to death (Figure 2D). In contrast, splenocytes
depleted of CD81 cells, alone or together with CD41
cells, did not induce eitherGVHD-associatedmortality
or sustained leukopenia in nontumor bearing mice. In
A20-bearing mice, recipients of either whole or CD41
T cell-depleted splenocytes had sustained engraftment
of donor CD41 (Figure 2A), CD81 (data not shown),
and B cells (Figure 2B), whereas recipients of spleno-
cytes depleted of CD81 cells, alone or together with
CD41 cells engrafted only transiently.The effect of do-
norT cell subset depletion on donor chimerismwas the
same in tumor-free versus tumor-bearing recipients of
donor lymphocyte infusions (data not shown). There-
fore, in immunocompetent recipients, the combination
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pletion of DLI abrogates sustained engraftment of donor cells administered after Cy. BALB/c mice (H-2d; n510/group) were conditioned with
Cy 200 mg/kg IP on day –1 and received 106 A20 lymphoma cells IV on Day 0. Mice received 5 107 spleen cells from fully MHC-mismatched
C57BL/6 (H-2b) donors onDay 0, either undepleted (C) or depleted of CD41T cells (B), CD81T cells (;), or both (6). Donor CD41T cell
(A) and B220 (B) chimerism in peripheral blood was measured on days 3, 7, 14, and 21 after DLI via staining for H-2Kb andH-2Kd antibody. (C)
CD8 depletion abrogates DLI-induced GVHD. BALB/c mice (H-2d; n510/group) were conditioned with Cy 200 mg/kg IP on day –1. Mice
received 5  107 spleen cells from fully MHC-mismatched C57BL/6 (H-2b) donors on Day 0, either undepleted (-) or depleted of CD41
T cells (C), CD81 T cells (:), or both (,). (D) CD8 depletion of DLI does not induce GVHD-associated aplasia. BALB/c mice (H-2d;
n510/group) were conditioned with Cy 200 mg/kg IP on day –1. Mice received 5  107 spleen cells from fully MHC-mismatched C57BL/6
(H-2b) donors on Day 0, either undepleted (-) or depleted of CD41 T cells (C), CD81 T cells (:), or 5  107 spleen cells from syngeneic
BALB/c mice (H-2d) (B).6 indicates theWBC in a naı¨ve BALB/c mouse. Peripheral white blood cell count was monitored via TruCOUNT
on days 3, 7, 14, and 21 after DLI. All experiments were repeated at least once.of Cy 1 CD82 allogeneic DLI induces antitumor
effects without DLI-associated toxicities.
A Direct Graft-versus-Tumor (GVT) Reaction Is
Not Required for Prolongation of Survival by Cy 1
CD82 DLI
A variety of mechanisms have been to proposed to
account for the antitumor effect of transiently engrafting
lymphocytes, including a direct GVT effect [25,26], or
the stimulation of endogenous antitumor immunity
[16-18]. In some instances, it has been shown that
a host-versus-graft reaction [27-29] can augment anti-
tumor immunity. We wished to characterize the anti-
tumor effect of a graft-versus-host (GVH) reaction in
the absence of any T cell-mediated host-versus-graft
or GVT effects. To do so, CB6 F1 mice bearing the
B16 melanoma, of B6 origin, were treated with Cyfollowed by nothing or DLI from syngeneic CB6 F1
or parental strain B6, or BALB/c donors. Whereas
BALB/c donors would induce both GVH reactions
and GVT effects, and CB6 F1 donors would provide
neither, the B6 donors are syngeneic to the tumor
and would induce only a GVH reaction. Recipients
of DLI from either parental strain prolonged survival
compared to recipients of either no DLI (Figure 3;
P5.04 and P5 .06 for B6 and BALB/c donors, respec-
tively) or DLI that was syngeneic to the recipient (P 5
.04 and .03 for B6 and BALB/c donors, respectively).
The results with B6 DLI demonstrate that a GVH
reaction is sufficient to prolong survival in the absence
of a direct GVT effect. The failure of CB6 F1 DLI to
prolong survival demonstrates that host expression of
alloantigens is required for the induction of antitumor
immunity.
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Effect of Cy 1 CD82 DLI
CD81 T cells have been shown to be capable of
mediating antitumor immunity in both mouse models
[30,31] and in human clinical trials [32]. Because
CD41T cells deliver help to CD81T cells by ‘‘licens-
ing’’ antigen-presenting cells [33-35], we postulated
that a donor CD41 T cell-mediated GVH reaction
effectively licenses host APCs to provide help to host-
derived, antitumor CD81 T cells. To characterize
the role of host CD81 T cells in the antitumor effect
of Cy 1 CD82 DLI, the A20 therapy experiment of
Figure 1C was repeated but with the addition of sepa-
rate groups of mice treated with the in vivo CD8-
depleting monoclonal antibody 2.43 on days 9 and 30
after tumor inoculation. Table 1 shows the effect of
antibody treatment on peripheral blood lymphocyte
populations in recipients of Cy1CD82DLI, and Fig-
ure 4 shows the effect of antibody treatment on the an-
titumor effect ofCy1CD82DLI. Several conclusions
Figure 3. Tumor expression of alloantigens is not required for the
beneficial effect of Cy plus CD8-depleted DLI. CB6 F1 mice (H-
2dxb; n 5 10/group) received 3  104 B16 melanoma cells i.v. on
day 0 followed by treatment with Cy 200 mg/kg i.p. on day 14 (-
), or Cy 200 mg/kg i.p. on day 14 and 5  107 spleen cells on day
15 from syngeneic (CB6F1) (,), 1 haplotype matched (C57Bl/6)
(C), or fully MHC mismatched (BALB/c) (B) donors, depleted of
CD81 T cells. The table included describes the GVT and GVH re-
lationships between the donor and recipient strains given that B16
melanoma is of B6 background. Results show: (C) v (-) P 5 .04,
(B) v (C) P 5 .06, (C) v (-) P 5 .04, (B) v (,) P 5 .03. All ex-
periments were repeated at least once.emerge from these data. First, depletion of host CD81
T cells was associated with a higher peak and longer
duration of donor CD41 T cell chimerism (Table 1),
implicating a role for hostCD81Tcells in determining
the kinetics of donor graft rejection. Second, the
survival of animals treated with Cy alone was longer
in antibody-untreated than in CD8-depleted mice
(Figure 4A; median survival, 99 versus 51 days,
P5.005). This result suggests that host CD81 T cells
contribute to the antitumor effect of Cy. Third, CD8-
depleted recipients ofCy1CD82DLI survived longer
than CD8-depleted recipients of Cy alone (Figure 4A;
median survival .130 versus 51 days, P 5 .005), sug-
gesting that allogeneic donor CD41 T cells mediate
an antitumor effect that does not require host CD81
T cells. Fourth, Cy 1 CD82 DLI was marginally
more effective in antibody-untreated than in anti-
body-treated recipients (Figure 4A; median survival
.130 days for both groups; P5 .08). This result raises
the possibility that host CD81Tcells participate in the
antitumor effect of Cy 1 CD82 DLI, and demon-
strates that prolonged survival of donor cells does not
guarantee a more potent antitumor effect.
In the A20 model system described above, a clear
role of host CD81 T cells in the antitumor effects of
CD82 DLI was difficult to discern because donor
CD41Tcells could kill tumor cells directly andbecause
the 2.43 antibody prolonged donor cell survival in addi-
tion to depleting host CD81 T cells. To eliminate the
possibility of a direct GVT effect of DLI, we examined
the effect of host CD81 cell depletion in B16-bearing
CB6 F1 recipients ofCy6B6CD8
2DLI, which is syn-
geneic to the tumor (Figure 4B). When host CD81 T
cells were not depleted, recipients of Cy 1 CD82
DLI survived significantly longer than recipients of Cy
alone (Figure 4B; median survival 56.5 versus 70 days,
P 5 .02). In contrast, when host CD81 T cells were
depleted, the recipients ofCy1CD82DLIdid not sur-
vive significantly longer than recipients of Cy alone
(Figure 4B; median survival 52.5 versus 53.5 days, P 5
.41). This result demonstrates that host CD81 cells
are required for the antitumor effect of CD82 DLI in
the treatment of metastatic B16 melanoma.
Additionally, because the antitumor effect of B6
CD82 DLI is abrogated completely by depleting
host CD81 T cells (Figure 4C), it rules out any direct
GVT effects from the donor B6 cells; otherwise, this
effect would have been seen even in the absence of
host CD81 T cells.
DISCUSSION
The results presented here demonstrate that tran-
siently engrafting allogeneic lymphocytes can mediate
the regression of established solid or hematologic
malignancies with minimal associated toxicity. Treat-
ment of tumor-bearing animals with Cy was required
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Median % CD81 Cells in Blood (SEM) Median % donor CD41 Chimerism (SEM)
Day after CD8- DLI No Depletion CD81 Depleted P No Depletion CD81 Depleted P
7 2.9 (0.76) 0.12 (0.03) .0006 7.9 (4.0) 26.9 (3.2) .01
14 5.3 (3.2) 0.30 (0.43) .03 0.54 (0.75) 31.7 (5.6) .0003
21 ND* 0.24 (0.13) — 0 (0) 0.32 (1.0) .02
28 ND 2.0 (0.69) — 0 (0) 0.63 (0.50) .02
BALB/c mice (H-2d; n 5 10/group) either depleted in vivo of CD81 T cells with 2.43 antibody on day 9 and every 3 weeks, or undepleted, re-
ceivedCy 200mg/kg i.p. on day 14, and 5 107 spleen cells from fullyMHC-mismatchedC57BL/6 (H-2b) donors, depleted of CD81T cells
on day 15. Donor CD41 cell chimerism (% of total CD41 cells) was measured weekly, from days 7-28, by staining tail blood with fluoro-
chrome-conjugated antibodies against CD4 and H-2Kb (donor). Percentage of host CD81 T cells in tail blood was also measured.
*ND, not determinedto unmask the antitumor activity of CD8-depleted
DLI. This antitumor activity involves at least 2 distinct
mechanisms: (1) a direct GVT effect that requires
CD41 T cells in the DLI and alloantigen expression
by the tumor itself, and (2) an indirect antitumor effect
mediated by host CD81 T cells and requiring a GVH
reaction against nonmalignant host tissue.
Although it is possible that the relative contribu-
tion of CD4 and CD8 cells in GVHD and GVT is
model specific, we have found that the combination
of Cy followed by CD82 DLI is effective at inducing
tumor regression without producing GVHD in 2 fully
MHC-mismatched and 1 MHC-haploidentical strain
combination (data not shown). We do find, however,
Figure 4.The antitumor effect of Cy plus CD8-depleted allogeneic DLI requires host CD81T cells and is mediated by both a direct GVT and
an indirect GVHD effect. (A) CD82 DLI mediates antitumor immunity through a GVT effect that requires direct tumor expression of alloan-
tigens. BALB/c mice (H-2d; n5 10/group) received 106 A20 cells i.v. on day 0, either alone (-) or followed by treatment with 2.43 antibody on
day 9 and every 3 weeks (,), or Cy 200 mg/kg i.p. on day 14 (:), or 2.43 antibody on day 9 and every 3 weeks, and Cy 200 mg/kg i.p. on day 14
(6), or Cy 200mg/kg i.p. on day 14 and 5 107 spleen cells from fullyMHC-mismatchedC57BL/6 (H-2b) donors, depleted of CD81T cells on
day 15 (C), or 2.43 antibody on day 9 and every 3 weeks, Cy 200 mg/kg i.p. on day 14, and 5  107 spleen cells from fully MHC-mismatched
C57BL/6 (H-2b) donors, depleted of CD81T cells on day 15 (B). Results show: (:) v (6) P5 .005, (B) v (6) P5 .005, (C) v (B) P5 .08. (B,
C) Cy 1 CD8-depleted DLI syngeneic to the tumor is sufficient to provide antitumor immunity. CB6F1 mice (H-2b; n 5 10/group) received
1.5 104 B16 melanoma cells i.v. on day 0 either alone (-) or followed by treatment with 2.43 antibody on day 9 and every 3 weeks (,), or Cy
200 mg/kg i.p. on day 14 (:), or 2.43 antibody on day 9 and every 3 weeks, and Cy 200 mg/kg i.p. on day 14 (6), or Cy 200 mg/kg i.p. on day 14
and 5 107 spleen cells from 1 haplotype matched C57BL/6 (H-2b) donors, depleted of CD81T cells on day 15 (C), or 2.43 antibody on day 9
and every 3 weeks, Cy 200mg/kg i.p. on day 14, and 5 107 spleen cells from 1 haplotypematchedC57BL/6 (H-2b) donors, depleted of CD81T
cells on day 15 (B). Results show: (C) v (:) P 5 .02, (B) v (6) P 5 .41. All experiments were repeated at least once.
506 H. J. Symons et al.that when the recipients’ tumor is MHC Class II1,
there are both direct and indirect antitumor effects
of donor CD41 T cells, whereas the antitumor effect
against MHC Class II2 tumors is indirect only, that
is, mediated by host CD81 T cells. We specifically
chose to study a variety of tumor models including
both hematologic and solid tumors of BALB/c back-
ground (A20 and RENCA, respectively), as well as
a solid tumor of C57BL/6 background (ie, B16) to
make our conclusions more generalizable and applica-
ble to a variety of cancer types.
Survival is not always a proper measure of a GVT
effect. However, we performed parallel transfers of al-
logeneic cells into tumor-free mice, and found that
the only groups withmortality were those that received
DLI containing CD81 T cells. These deaths were
GVHD related, as mice exhibited ruffled fur, hunched
posture, diarrhea, andweight loss (datanot shown).Tu-
mor-free mice that received Cy with or without CD82
DLI appeared healthy and survived long term. From
this, we conclude that CD81 T cells are required for
GVHD-associated mortality, and that deaths among
tumor-bearing mice not receiving CD81 T cells were
attributable to complications of progressive tumor.
Previous studies have demonstrated an antitumor
effect of allogeneic or even xenogeneic lymphocyte in-
fusions given to unconditioned or minimally condi-
tioned humans [13,15,36-44] or experimental animals
[16,18,26,45,46]. A variety of mechanisms have been
invoked to explain tumor regression induced by tran-
siently engrafting DLI, including transient GVT
responses mediated by donor T cells or NK cells
[12,26,46-48], conditioning effects on host immunity
[49,50], or even abrogation of host tolerance by cyto-
kines liberated during the rejection reaction [27,29].
Moreover, immunosuppressive conditioning has been
shown to augment the capacity of adoptively trans-
ferred allogeneic cells to induce GVHD [51] or GVT
effects [46], and recent studies have shown that lym-
phopenia-induced proliferation per se is sufficient to
augment antitumor immunity by adoptively trans-
ferred T cells [52,53]. We are currently investigating
why Cy pretreatment is required to unmask the antitu-
mor activity of CD82DLI in animals with established
tumors. Preliminary experiments demonstrate that Cy
mitigates the inhibitory influence of tumor-induced,
Foxp31 regulatory T cells (H.J.S. and E.J.F., unpub-
lished data), but other explanations remain possible,
such as the enhancement of tumor- and allo-antigen
presentation resulting from the Cy-induced apoptosis
of tumor and host cells. Any or all of these mechanisms
may be contributing to the antitumor effect of tran-
siently engrafting DLI in our models. Indeed, results
in the A20 model demonstrate that at least some of
the antitumor effect of CD8-depleted DLI is indepen-
dent of host CD81 T cells (Figure 4), and thus may be
produced directly by donor lymphocytes. However,when the donor lymphocytes were syngeneic to the
tumor, an antitumor effect of allogeneic lymphocyte
infusion that is dependent upon the presence of host
CD81 T cells became evident, suggesting that donor
CD41 T cells and host CD81 T cells cooperate to in-
duce tumor regression. This implies that the reason
that CD8-depleted recipients of Cy1CD82DLI sur-
vived longer than CD8-depleted recipients of Cy alone
in the A20 model (Figure 4A), but not in the B16 mel-
anoma model (Figures 4B-C), may be explained by
direct tumor recognition of MHC class II on A20
tumor cells, an event that would not occur with B16
because it does not express MHC Class II molecules.
Taken together, the results of Figure 4 suggest that
CD82 DLI mediates antitumor effects through 2 dis-
tinct mechanisms—a direct GVT effect that requires
direct tumor expression of alloantigens, and an indirect
antitumor effect that is mediated by host CD81T cells
and does not require tumor expression of alloantigens.
Therefore, CD81Tcells of host originmay play a crit-
ical role in producing tumor regression in the context
of a GVH reaction, as described here, or in a host-
versus-graft reaction, as described previously by Sykes
and colleagues [29].
The idea that a GVH reaction could awaken a dor-
mant antitumor response from the host was first pro-
posed by Alexander and colleagues [16]. The term
‘‘allogeneic effect’’ was originally coined to describe
how a GVH reaction could substitute for cognate T
cell help in the secondary antibody response to a hapten
[54], but was extended to describe how an allogeneic
lymphocyte infusion could augment host resistance to
a subsequent tumor challenge, even at a time when
the donor cells had been rejected. Because of limita-
tions in existing technology, these early studies could
not define the precise cellular interactions involved in
the antitumor effect of transiently engrafting lympho-
cytes [17,18,45]. The current study describes a novel
cooperation between donor CD41 and host CD81 T
cells in mediating an antitumor effect against a subse-
quent tumor challenge as well as against an established
burden of either a solid or hematologic malignancy.
Because CD41 T cells provide ‘‘help’’ to CD81 cyto-
toxic T cells by activating APCs [33-35], it seems rea-
sonable to propose that alloreactive donor CD41 T
cells recognize and activate host APCs, which in turn,
can activate tumor-specific host CD81 T cells even
after the donor CD41 T cells have been rejected.
This model is consistent with the finding that alloanti-
gen expression by nonmalignant host tissue is sufficient
for an antitumor effect of parental DLI given to an F1
host (Figure 3A).
Allogeneic BMT has an established role in the
treatment of a variety of hematologic malignancies
through the induction of a GVT effect. Although there
has been no dearth of attempts to apply alloBMT to
the treatment of advanced solid tumors, results have
The Allogeneic Effect Revisited 507been mixed at best. A putative GVT effect of alloBMT
has been demonstrated against a variety of solid tu-
mors [55], including renal cell carcinoma [56], breast
cancer [57,58], colon cancer [59], and ovarian carci-
noma [60], but the antitumor effect usually occurs in
the context of GVHD, and no conclusive benefits in
overall or event-free survival have been reported [61].
In contrast, Cy 1 CD82 DLI induced antitumor
effects against systemically disseminated solid tumors
with minimal toxicity. Although encouraging, these
results need to be confirmed inmore clinically relevant
models, such as the treatment of endogenous rather
than transplanted tumors. We postulate that distinct
populations of T cells mediate antitumor effects after
alloBMT versus Cy 1 CD82 DLI. The antitumor ef-
fectors after myeloablative alloBMT are thought to be
donor T cells reactive to host minor histocompatibility
antigens. Although these T cells can cure hematologic
malignancies through a lymphohematopoietic GVH
reaction that destroys both normal and malignant
blood cells, there is no a priori reason for them to be
able to distinguish between normal and malignant
solid tissue. In contrast, at least some of the antitumor
effectors of Cy 1 CD82 DLI are host CD81 T cells,
which are presumably tolerant to normal peripheral
self tissues. It is possible that the systemic activation
of host APCs by alloreactive donor CD41 T cells
could also unmask the activity of autoreactive T and/
or B cell clones. Although we have not rigorously eval-
uated the mice for autoimmune phenomena, none was
clinically evident (data not shown).
The results described herein demonstrate that che-
motherapy, with or without adoptive cellular immuno-
therapy, works best in the presence of an intact host
CD81 T cell compartment. Indeed, the participation
of host CD81T cells in the antitumor response to che-
motherapy (Figure 4A) may explain why the pretreat-
ment absolute lymphocyte count correlates with the
response to chemotherapy of lymphoma [62] and solid
tumors [63]. By the same token, it is also possible that
chemotherapy-induced lymphopenia underlies the
inexorable decline in responsiveness of metastatic solid
tumors to cytotoxic drugs. If, as our results suggest, the
optimal response to immunotherapy requires an intact
host immune system, then the sequence of trying im-
munotherapy after the failure of standard chemother-
apy would appear to be counterproductive. Likewise,
the strategy of intensive, nonselective lymphodepletion
prior to adoptive immunotherapy [32,64,65] makes
sense only when donor cells are the sole mediators of
antitumor immunity.
Finally, our results support a strategy of awakening
dormant antitumor immunity against advanced cancer
by providing exogenous CD41 T cell help for endog-
enous tumor-specific CD81 T cells [66]. The capacity
of a GVH reaction to provide this help suggests that
allogeneic lymphocytes are a readily available tool forbreaking functional tolerance to advanced cancers in
the clinic.
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